BioCryst to Report Third Quarter 2012 Financial Results on November 8, 2012

  BioCryst to Report Third Quarter 2012 Financial Results on November 8, 2012

Business Wire

RESEARCH TRIANGLE PARK, N.C. -- November 01, 2012

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third
quarter 2012 financial results will be released on Thursday, November 8, 2012.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to
discuss the financial results and to provide an update on the Company’s
programs. The call will be led by Jon P. Stonehouse, President and Chief
Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief
Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief
Medical Officer.

The webcast can be accessed by logging onto Please connect
to the website at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be needed. To participate in
the conference call, please dial 1-877-303-8027 (United States) or
1-760-536-5165 (International). No passcode is needed for the call.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule
drugs that block key enzymes involved in infectious and inflammatory diseases.
BioCryst currently has two late-stage development programs: peramivir, a viral
neuraminidase inhibitor for the treatment of influenza, and ulodesine
(BCX4208), a purine nucleoside phosphorylase (PNP) inhibitor for the treatment
of gout. In addition, BioCryst is developing two preclinical compounds:
BCX5191, a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for
hepatitis C, and BCX4161, an oral inhibitor of plasma kallikrein for
hereditary angioedema. Utilizing state-of-the-art structure-guided drug design
and crystallography, BioCryst continues to discover innovative compounds with
the goal of addressing unmet medical needs of patients and physicians. For
more information, please visit the Company's website at

This press release contains forward-looking statements, including statements
regarding future results and achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements to be materially different from any
future results, performances or achievements expressed or implied by the
forward-looking statements. Please refer to the documents BioCryst files
periodically with the SEC and located at



BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910
Press spacebar to pause and continue. Press esc to stop.